Novartis India Limited

NSEI:NOVARTIND Stock Report

Market Cap: ₹22.6b

Novartis India Past Earnings Performance

Past criteria checks 4/6

Novartis India has been growing earnings at an average annual rate of 12.7%, while the Pharmaceuticals industry saw earnings growing at 16.2% annually. Revenues have been declining at an average rate of 6.7% per year. Novartis India's return on equity is 10.9%, and it has net margins of 23.5%.

Key information

12.7%

Earnings growth rate

13.2%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate-6.7%
Return on equity10.9%
Net Margin23.5%
Next Earnings Update25 Jan 2024

Recent past performance updates

Recent updates

Factors Income Investors Should Consider Before Adding Novartis India Limited (NSE:NOVARTIND) To Their Portfolio

Apr 04
Factors Income Investors Should Consider Before Adding Novartis India Limited (NSE:NOVARTIND) To Their Portfolio

Weak Financial Prospects Seem To Be Dragging Down Novartis India Limited (NSE:NOVARTIND) Stock

Jan 29
Weak Financial Prospects Seem To Be Dragging Down Novartis India Limited (NSE:NOVARTIND) Stock

Are Dividend Investors Getting More Than They Bargained For With Novartis India Limited's (NSE:NOVARTIND) Dividend?

Jan 02
Are Dividend Investors Getting More Than They Bargained For With Novartis India Limited's (NSE:NOVARTIND) Dividend?

Novartis India Limited's (NSE:NOVARTIND) Popularity With Investors Is Under Threat From Overpricing

Dec 07
Novartis India Limited's (NSE:NOVARTIND) Popularity With Investors Is Under Threat From Overpricing

We're Not Counting On Novartis India (NSE:NOVARTIND) To Sustain Its Statutory Profitability

Nov 08
We're Not Counting On Novartis India (NSE:NOVARTIND) To Sustain Its Statutory Profitability

Is Novartis India Limited's (NSE:NOVARTIND) Recent Performance Market's Way Of Responding to Its Mixed Financials?

Oct 11
Is Novartis India Limited's (NSE:NOVARTIND) Recent Performance Market's Way Of Responding to Its Mixed Financials?

Revenue & Expenses Breakdown

How Novartis India makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:NOVARTIND Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 233,2577663290
30 Jun 233,4847123920
31 Mar 233,7871,0344230
31 Dec 224,0095505810
30 Sep 224,1975377510
30 Jun 224,2274249070
31 Mar 223,999-371,0940
31 Dec 214,0082941,1550
30 Sep 213,9572231,1890
30 Jun 213,8702281,1690
31 Mar 213,8142091,1870
31 Dec 203,7581801,2480
30 Sep 203,9952641,2600
30 Jun 204,2141371,2790
31 Mar 204,3831011,2820
31 Dec 194,5492281,3930
30 Sep 194,7312801,3570
30 Jun 194,6194261,3970
31 Mar 194,9075181,4800
31 Dec 185,0565871,7260
30 Sep 185,2616461,8460
30 Jun 185,8728131,8900
31 Mar 185,6397841,8360
31 Dec 175,8405481,8500
30 Sep 175,9234911,8320
30 Jun 175,9974521,7250
31 Mar 176,5625721,8140
31 Dec 166,4558361,1380
30 Sep 166,7341,2901,2220
30 Jun 167,2232,1041,3820
31 Mar 166,9307252,0060
31 Dec 157,3059261,6680
30 Sep 157,6018361,8050
30 Jun 157,7057851,7820
31 Mar 157,5527931,6710
31 Dec 148,6385584,4180
30 Sep 148,6936754,2560
30 Jun 148,5079904,1910
31 Mar 147,2768571,4650
31 Dec 138,7209913,9240
30 Sep 138,8191,1283,9400
30 Jun 139,0711,0663,8950
31 Mar 139,0341,1973,8470

Quality Earnings: NOVARTIND has a high level of non-cash earnings.

Growing Profit Margin: NOVARTIND's current net profit margins (23.5%) are higher than last year (12.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NOVARTIND's earnings have grown by 12.7% per year over the past 5 years.

Accelerating Growth: NOVARTIND's earnings growth over the past year (42.6%) exceeds its 5-year average (12.7% per year).

Earnings vs Industry: NOVARTIND earnings growth over the past year (42.6%) exceeded the Pharmaceuticals industry 20.5%.

Return on Equity

High ROE: NOVARTIND's Return on Equity (10.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/22 13:50
End of Day Share Price 2023/10/25 00:00
Earnings2023/09/30
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novartis India Limited is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Amit GuptaBatlivala & Karani Securities India Pvt. Ltd.
Anil BurraFirstCall Research
Suhani AdilabadkarFirstCall Research